A. D. Singh, M. E. Turell, and A. K. Topham, Uveal melanoma: trends in incidence, treatment, and survival, Ophthalmology, vol.118, issue.9, pp.1881-1885, 2011.

E. Kujala, T. Makitie, and T. Kivela, Very long-term prognosis of patients with malignant uveal melanoma, Invest Ophthalmol Vis Sci, vol.44, issue.11, pp.4651-4659, 2003.

M. Diener-west, S. M. Reynolds, and D. J. Agugliaro, Screening for metastasis from choroidal melanoma: the collaborative ocular melanoma study group report 23, J Clin Oncol, vol.22, issue.12, pp.2438-2444, 2004.

, Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15, Arch Ophthalmol, vol.119, pp.670-676, 2001.

S. E. Coupland, S. L. Lake, M. Zeschnigk, and B. E. Damato, Molecular pathology of uveal melanoma, Eye (Lond), vol.27, issue.2, pp.230-242, 2013.

M. D. Onken, L. A. Worley, and D. H. Char, Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma, Ophthalmology, vol.119, issue.8, pp.1596-1603, 2012.

M. G. Field, C. L. Decatur, and S. Kurtenbach, PRAME as an independent biomarker for metastasis in uveal melanoma, Clin Cancer Res, vol.22, issue.5, pp.1234-1242, 2016.

M. Martin, L. Maßhöfer, and P. Temming, Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nat Genet, vol.45, issue.8, pp.933-936, 2013.

J. W. Harbour, M. D. Onken, and E. D. Roberson, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, issue.6009, pp.1410-1413, 2010.

A. R. Moore, E. Ceraudo, and J. J. Sher, Recurrent activating mutations of Gprotein-coupled receptor CYSLTR2 in uveal melanoma, Nat Genet, vol.48, issue.6, pp.675-680, 2016.

J. J. Augsburger, Z. M. Correa, and A. H. Shaikh, Effectiveness of treatments for metastatic uveal melanoma, Am J Ophthalmol, vol.148, issue.1, pp.119-127, 2009.

R. D. Carvajal, J. A. Sosman, and J. F. Quevedo, Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial, JAMA, vol.311, issue.23, pp.2397-2405, 2014.

R. Dummer, A. Hauschild, and N. Lindenblatt, Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and followup, Ann Oncol, vol.26, issue.5, pp.126-132, 2015.

R. D. Carvajal, S. Piperno-neumann, and E. Kapiteijn, Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT), J Clin Oncol, vol.36, issue.12, pp.1232-1239, 2018.

K. Buder, A. Gesierich, G. Gelbrich, and M. Goebeler, Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives, Cancer Med, vol.2, issue.5, pp.674-686, 2013.

M. Diener-west, S. M. Reynolds, and D. J. Agugliaro, Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no, Arch Ophthalmol, vol.123, issue.26, pp.1639-1643, 2005.

D. Gomez, C. Wetherill, and J. Cheong, The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection, J Surg Oncol, vol.109, issue.6, pp.542-547, 2014.

E. L. Korn, P. Y. Liu, and S. J. Lee, Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials, J Clin Oncol, vol.26, issue.4, pp.527-534, 2008.

D. Moher, A. Liberati, and J. Tetzlaff, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, vol.339, p.2535, 2009.

S. B. Edge, M. A. Carducci, and C. C. Compton, AJCC Cancer Staging Manual, 2009.

R. P. A'hern, Sample size tables for exact single-stage phase II designs, Stat Med, vol.20, issue.6, pp.859-866, 2001.

S. Chow and H. Wang, Sample Size Calculations in Clinical Research, 2008.

J. L. Fleiss, B. Levin, and M. C. Paik, Statistical Methods for Rates and Proportions, 2003.

J. M. Lachin and . Methods, , 2000.

D. Machin, M. Campbell, P. Fayers, and A. Pinol, Sample Size Tables for Clinical Studies, 1997.

T. P. Ryan, Sample Size Determination and Power, 2013.

K. F. Bol, H. W. Mensink, and E. H. Aarntzen, Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients, Am J Ophthalmol, vol.158, issue.5, pp.939-947, 2014.

A. M. Joshua, J. G. Monzon, and C. Mihalcioiu, A phase 2 study of tremelimumab in patients with advanced uveal melanoma, Melanoma Res, vol.25, issue.4, pp.342-347, 2015.

P. Rodriguez, J. M. Ochoa-de-olza, M. Codes, and M. , Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): the GEM-1 trial, J Clin Oncol, vol.32, p.9033, 2014.

L. Zimmer, J. Vaubel, and P. Mohr, Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma, PLoS One, vol.10, issue.3, p.118564, 2015.

T. Kivela, S. Suciu, and J. Hansson, Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma, Eur J Cancer, vol.39, pp.1115-1120, 2003.

P. D. Nathan, E. Marshall, and C. T. Smith, A cancer research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM), ASCO Meeting Abstr, vol.30, p.8523, 2012.

A. Mahipal, L. Tijani, and K. Chan, A pilot study of sunitinib malate in patients with metastatic uveal melanoma, Melanoma Res, vol.22, issue.6, pp.440-446, 2012.

N. Penel, C. Delcambre, and X. Durando, O-Mel-Inib: a Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma, Invest New Drugs, vol.26, issue.6, pp.561-565, 2008.

S. Bhatia, J. Moon, and K. A. Margolin, Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512, PLoS One, vol.7, issue.11, p.48787, 2012.

F. Mouriaux, V. Servois, and J. J. Parienti, Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study, Br J Cancer, vol.115, issue.1, pp.20-24, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01481462

A. A. Tarhini, P. Frankel, and K. A. Margolin, Aflibercept (VEGF trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin, Clin Cancer Res, vol.17, issue.20, pp.6574-6581, 2011.

S. Piperno-neumann, A. Diallo, and E. Mc, Phase II trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic uveal melanoma, Oncologist, vol.21, issue.3, pp.281-282, 2016.

C. Pfohler, I. A. Cree, and S. Ugurel, Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study, Anticancer Drugs, vol.14, pp.337-340, 2003.

S. Leyvraz, S. Piperno-neumann, and S. Suciu, Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial, Ann Oncol, vol.25, issue.3, pp.742-746, 2014.

A. Y. Bedikian, N. Papadopoulos, and C. Plager, Phase II evaluation of temozolomide in metastatic choroidal melanoma, Melanoma Res, vol.13, issue.3, pp.303-306, 2003.

J. Homsi, A. Y. Bedikian, and N. E. Papadopoulos, Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma, Melanoma Res, vol.20, issue.6, pp.507-510, 2010.

U. Keilholz, R. Schuster, and A. Schmittel, A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours, Eur J Cancer, vol.40, issue.14, pp.2047-2052, 2004.

A. Schmittel, M. Schmidt-hieber, and P. Martus, A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma, Ann Oncol, vol.17, issue.12, pp.1826-1829, 2006.

A. Schmittel, R. Schuster, and N. E. Bechrakis, A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma, Melanoma Res, vol.15, issue.5, pp.447-451, 2005.

T. Sato, D. J. Eschelman, and C. F. Gonsalves, Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocytemacrophage colony-stimulating factor, J Clin Oncol, vol.26, issue.33, pp.5436-5442, 2008.

L. B. Van-iersel, E. J. Hoekman, and H. Gelderblom, Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases, Ann Surg Oncol, vol.15, pp.1891-1898, 2008.

P. E. Huppert, G. Fierlbeck, and P. Pereira, Transarterial chemoembolization of liver metastases in patients with uveal melanoma, Eur J Radiol, vol.74, issue.3, pp.38-44, 2010.

K. Patel, K. Sullivan, and D. Berd, Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study, Melanoma Res, vol.15, issue.4, pp.297-304, 2005.

M. E. Valsecchi, M. Terai, and D. J. Eschelman, Double-blinded, randomized phase II study using embolization with or without granulocytemacrophage colony-stimulating factor in uveal melanoma with hepatic metastases, J Vasc Interv Radiol, vol.26, issue.4, pp.523-532, 2015.

T. Vogl, K. Eichler, and S. Zangos, Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival, J Cancer Res Clin Oncol, vol.133, issue.3, pp.177-184, 2007.

G. Fiorentini, C. Aliberti, D. Conte, and A. , Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study, In Vivo, vol.23, pp.131-137, 2009.

P. A. Gimotty, D. Guerry, and K. Flaherty, Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients, J Clin Oncol, vol.26, issue.4, pp.517-518, 2008.

S. Valpione, J. C. Moser, and R. Parrozzani, Development and external validation of a prognostic nomogram for metastatic uveal melanoma, PLoS One, vol.10, issue.3, p.120181, 2015.

S. Eskelin, S. Pyrhonen, and M. Hahka-kemppinen, A prognostic model and staging for metastatic uveal melanoma, Cancer, vol.97, issue.2, pp.465-475, 2003.

T. T. Kivela, S. Piperno-neumann, and L. Desjardins, Validation of a prognostic staging for metastatic uveal melanoma: a collaborative study of the European Ophthalmic Oncology Group, Am J Ophthalmol, vol.168, pp.217-226, 2016.

P. Rietschel, K. S. Panageas, and C. Hanlon, Variates of survival in metastatic uveal melanoma, J Clin Oncol, vol.23, issue.31, pp.8076-8080, 2005.